10 Minutes to a Better Building: Finding Utility Incentives for Your Building

Building owners and property managers may be familiar with the various rebates and programs associated with equipment within the scope of their buildings. Still, there are other utility incentives available that aren’t as known. Emily Herchenroeder, Energy Solutions Team Leader at Boland, joined Tyler Kern to shed more light on some of those other utility rebates and incentives.

“The purpose of the incentive program is pretty simple,” Herchenroeder said. “It’s designed to reduce demand on the utility grid by incentivizing businesses to do capital improvement projects at a fraction of the cost.” It’s a two-part saving with money back through rebates and cash saved through energy usage reduction.

One example of a beneficial incentive Herchenroeder pointed to was AFDs. “We found a chiller plant in D.C. that qualified for a really good rebate for AFDs,” Herchenroeder said. “Since Washington, D.C. already has a relatively expensive electricity rate, we found this payback was for one AFD, roughly one-to-three years payback, and then a second drive would be five years or less for both.”

Belimo Energy Valves are another item Boland’s found incentive opportunities for clients. “Boland did a retrofit project in Berkeley County where a number of outdated system components were replaced with Belimo Energy Valves,” Herchenroeder said. “This reduced their HVAC energy usage by more than half.” Once installed, these sophisticated valves helped detect flaws within the existing piping of this Berkely County project.

In a recent project Boland developed with a client, they found a significant rebate using dynamic air filters. “In this particular project, we estimated enough kWh savings to produce a rebate of almost a hundred and six thousand dollars,” Herchenroeder said. “That’s a large and substantial key factor in moving forward with a project. Not only are you reducing your energy usage, you’re getting a rebate back, and drastically improving indoor air quality.”

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More